Pneumonitis Risk After Chemoradiotherapy With and Without Immunotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pneumonitis Risk After Chemoradiotherapy With and Without Immunotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Published:2024-07 Issue:4 Volume:119 Page:1179-1207
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Han Chong,Qiu Jingping,Bai Lu,Liu Tingting,Chen Jun,Wang He,Dang Jun^ORCID

Publisher

Elsevier BV

Reference191 articles.

1. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer;Antonia;N Engl J Med,2017

2. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial

3. Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer;Jung;Lung Cancer,2020

4. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews;Page;BMJ,2021

5. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group;Stroup;JAMA,2000

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer;Scientific Reports;2024-08-23

2. Immune checkpoint inhibition in early-stage non-small cell lung cancer;Lung Cancer;2024-07

3. Evaluation of chest CT-scans following lung stereotactic ablative radiotherapy: Challenges and new insights;Lung Cancer;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3